Skip to main content
. 2020 May 11;11(5):353. doi: 10.1038/s41419-020-2566-1

Fig. 3. SC66 inhibits AKT-mTOR activation in RCC cells.

Fig. 3

786-O cells, the primary human RCC cells (“RCC1/2”), or the renal epithelial cells (“Ren_Epi”) were treated with SC66 (3 μM) for 2 h, expression of listed proteins in total cell lysates were tested by Western blotting assay (a, b, and f).The quantified results integrating five sets of blotting data were presented (c–e). 786-O cells or RCC1/2 primary cells were treated with SC66 (3 μM), together with or without Erk inhibitor PD98059/U0126 (each at 5 μM), cells were further cultured for 72 h, and cell viability and apoptosis tested by MTT (g) and nuclear TUNEL staining (h) assays, respectively. Data were expressed as the mean ± standard deviation (S.D.). “DMSO” stands for 0.1% DMSO (g, h). *P < 0.05 vs. “Veh” group. #P < 0.05 vs. “DMSO” plus SC66 treatment (g, h). In this figure, experiments were repeated three times, and similar results were obtained each time.